Bispecific VEGF-ANG-2 Antibody Dosing for Macular Edema Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular vascular diseases such as age-related macular degeneration and diabetic macular edema, which involve blocking vascular endothelial growth factor (VEGF) to halt abnormal vessel growth, do not address underlying ischemia and may exacerbate the condition, and systemic anti-VEGF therapies pose risks.
Innovation Solution
Administration of a bispecific antibody that binds to both VEGF and angiopoietin-2 (ANG-2) intravitreally at intervals of every 8 weeks or less, targeting both factors to promote beneficial vessel growth while reducing systemic exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-VEGF therapy is administered to inhibit abnormal vessel growth, then pathological angiogenesis is reduced, but beneficial collateral vessel growth is also inhibited and underlying ischemia is not addressed
Solution Approach 1:
The patent applies local quality by delivering the antibody fragment directly to the ocular tissue through intravitreal or subconjunctival administration. This localized delivery ensures high concentration at the target site for effective inhibition of pathological angiogenesis while minimizing systemic exposure that would block beneficial collateral vessel growth in other tissues.
Solution Approach 2:
The patent uses a antibody fragment (Fab or scFv) instead of a full IgG molecule. This segmentation removes the Fc portion that mediates systemic effects and immune activation, retaining only the antigen-binding functionality. This allows selective inhibition of VEGF in the eye without the systemic toxicities associated with full antibodies.
2Reliability
If systemic blockade of VEGF is implemented, then widespread angiogenesis is inhibited, but the risk of systemic toxicities increases
Solution Approach 1:
The invention achieves local concentration of the therapeutic agent in the ocular tissue through direct administration routes (intravitreal injection or subconjunctival placement). This creates a high local drug concentration sufficient for therapeutic effect while maintaining low systemic levels, thereby preventing systemic toxicities.
Solution Approach 2:
The patent extracts only the essential antigen-binding portion of the antibody (the Fab or scFv fragment) and removes the Fc portion that is responsible for systemic immune effects and toxicity. This extracted fragment retains the ability to bind and inhibit VEGF locally without causing systemic adverse events.
3Reliability
If frequent dosing is administered to maintain therapeutic effect, then disease activity is better controlled, but treatment complexity and patient burden increase
Solution Approach 1:
The patent employs sustained-release delivery systems such as implantable devices or hydrogels that pre-load and gradually release the antibody fragment over extended periods (months). This preliminary action of loading the delivery system allows maintenance of therapeutic concentrations without requiring frequent patient visits for re-dosing.
Solution Approach 2:
The invention transitions from frequent periodic dosing to extended periodic dosing through sustained-release mechanisms. The drug is released over long intervals (e.g., every 3-6 months instead of every 4 weeks), converting a high-frequency periodic action into a low-frequency periodic action that reduces patient burden while maintaining efficacy.
Data Source
AI summary
The current invention relates to the use of bispecific antibodies that bind to human vascular endothelial growth factor (VEGF) and to human angiopoietin-2 (ANG-2) for the treatment of ophthalmologic diseases, such as age-related macular degeneration and diabetic macular edema, where the bispecific antibodies are administered intravitreally every 8 weeks or less frequently.